New drug combinations show improved survival rates for chronic lymphocytic leukemia patients.

A study at the ASH Annual Meeting showed that a combination of acalabrutinib and venetoclax, with or without obinutuzumab, improved progression-free survival in patients with untreated chronic lymphocytic leukemia. The 36-month progression-free survival rates were 83.1% and 76.5% for the combination therapies versus 66.5% for standard treatment. The study suggests these new therapies could become a fixed-duration treatment option with better outcomes.

December 08, 2024
20 Articles